302 related articles for article (PubMed ID: 11522017)
81. Plasminogen activator inhibitor-1 and outcome after femoropopliteal angioplasty: analysis of genotype and plasma levels.
Mlekusch W; Schillinger M; Exner M; Sabeti S; Mannhalter C; Minar E; Wagner O
Thromb Haemost; 2003 Oct; 90(4):717-23. PubMed ID: 14515194
[TBL] [Abstract][Full Text] [Related]
82. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
Primrose JN; Davies JA; Prentice CR; Hughes R; Johnston D
Thromb Haemost; 1992 Oct; 68(4):396-9. PubMed ID: 1448769
[TBL] [Abstract][Full Text] [Related]
83. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Juhan-Vague I; Vague P; Alessi MC; Badier C; Valadier J; Aillaud MF; Atlan C
Diabete Metab; 1987 Jul; 13(3 Pt 2):331-6. PubMed ID: 3115843
[TBL] [Abstract][Full Text] [Related]
84. Role of -675 4G/5G in the plasminogen activator inhibitor-1 gene and -308G/A tumor necrosis factor-α gene polymorphisms in obese Argentinean patients.
Wingeyer SD; Graffigna MN; Belli SH; Benetucci J; de Larrañaga GF
Genet Test Mol Biomarkers; 2012 May; 16(5):372-5. PubMed ID: 22106856
[TBL] [Abstract][Full Text] [Related]
85. Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children.
de la Cruz-Mosso U; Muñoz-Valle JF; Salgado-Bernabé AB; Castro-Alarcón N; Salgado-Goytia L; Sánchez-Corona J; Flores-Martínez SE; Parra-Rojas I
J Pediatr (Rio J); 2013; 89(5):492-8. PubMed ID: 23871496
[TBL] [Abstract][Full Text] [Related]
86. Global fibrinolytic activity, PAI-1 level, and 4G/5G polymorphism in Thai children with arterial ischemic stroke.
Natesirinilkul R; Sasanakul W; Chuansumrit A; Kadegasem P; Visudtibhan A; Wongwerawattanakoon P; Sirachainan N
J Stroke Cerebrovasc Dis; 2014; 23(10):2566-2572. PubMed ID: 25284719
[TBL] [Abstract][Full Text] [Related]
87. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause--influence of hormone replacement therapy.
Estellés A; Cano A; Falcó C; España F; Gilabert J; Grancha S; Aznar J
Thromb Haemost; 1999 Jan; 81(1):104-10. PubMed ID: 10348700
[TBL] [Abstract][Full Text] [Related]
88. Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea.
Barceló A; Llompart E; Barbé F; Morlá M; Vila M; Agustí AG
Respir Med; 2002 Mar; 96(3):193-6. PubMed ID: 11908512
[TBL] [Abstract][Full Text] [Related]
89. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock.
Westendorp RG; Hottenga JJ; Slagboom PE
Lancet; 1999 Aug; 354(9178):561-3. PubMed ID: 10470701
[TBL] [Abstract][Full Text] [Related]
90. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk.
Hoekstra T; Geleijnse JM; Schouten EG; Kluft C
Thromb Haemost; 2004 May; 91(5):861-72. PubMed ID: 15116245
[TBL] [Abstract][Full Text] [Related]
91. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
Song J; Yoon YM; Jung HJ; Hong SH; Park H; Kim JQ
J Korean Med Sci; 2000 Apr; 15(2):146-52. PubMed ID: 10803689
[TBL] [Abstract][Full Text] [Related]
92. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly.
Hoekstra T; Geleijnse JM; Kluft C; Giltay EJ; Kok FJ; Schouten EG
Stroke; 2003 Dec; 34(12):2822-8. PubMed ID: 14605330
[TBL] [Abstract][Full Text] [Related]
93. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
[TBL] [Abstract][Full Text] [Related]
94. Fibrinolytic gene polymorphism and ischemic stroke.
Jood K; Ladenvall P; Tjärnlund-Wolf A; Ladenvall C; Andersson M; Nilsson S; Blomstrand C; Jern C
Stroke; 2005 Oct; 36(10):2077-81. PubMed ID: 16179568
[TBL] [Abstract][Full Text] [Related]
95. The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
Ozel Demiralp D; Aktas H; Akar N
Clin Appl Thromb Hemost; 2008 Oct; 14(4):438-46. PubMed ID: 18160587
[TBL] [Abstract][Full Text] [Related]
96. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.
Nikfardjam M; Graf S; Beckmann R; Hornykewycz S; Koller-Strametz J; Binder BR; Huber K
Thromb Haemost; 1999 Sep; 82 Suppl 1():80-4. PubMed ID: 10695493
[TBL] [Abstract][Full Text] [Related]
97. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
Tschoner A; Sturm W; Engl J; Kaser S; Laimer M; Laimer E; Klaus A; Patsch JR; Ebenbichler CF
Nutr Metab Cardiovasc Dis; 2012 Apr; 22(4):340-6. PubMed ID: 21093232
[TBL] [Abstract][Full Text] [Related]
98. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
Panahloo A; Mohamed-Ali V; Lane A; Green F; Humphries SE; Yudkin JS
Diabetes; 1995 Jan; 44(1):37-42. PubMed ID: 7813812
[TBL] [Abstract][Full Text] [Related]
99. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease.
Wiman B
Thromb Haemost; 1995 Jul; 74(1):71-6. PubMed ID: 8578529
[TBL] [Abstract][Full Text] [Related]
100. Relationship between changes in plasma leptin concentrations and plasminogen activator inhibitor-1 in obese prepubertal children after nine months of treatment.
Valle Jiménez M; Martos R; Morales RM; Valle R; Cañete MD; Urbano MM; Bermudo F; Cañete R
Ann Nutr Metab; 2013; 63(3):216-22. PubMed ID: 24135306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
